

**UCSF Benioff Children's Hospital**  
**Antimicrobial Dosing Guideline for Infants and Children > 1 Month of Age**

*Approved by Pharmacy and Therapeutics Committee (11/98) Last Update 5/2019*

<b>Antimicrobial Stewardship Program (ASP)</b>	Call M-F 8am-5pm for focused questions on antimicrobial selection, dose, monitoring, duration of therapy and for approvals (Voalte: Pediatric Antimicrobial Stewardship Team - ID/ASP Pharmacist or Provider)	Contact via Voalte
<b>Pediatric ID Consult Service</b>	For cases requiring in depth review and physician consultation	443-2384 (pager)
<b>Online Resources</b>	<b>Pediatric Empiric Antimicrobial Therapy Guidelines</b> , Clinical Pathways, Detailed Guidelines, Antimicrobial Susceptibility Profiles	<a href="http://idmp.ucsf.edu">idmp.ucsf.edu</a>

Shaded boxes indicate ID-Restricted agents (**ID-R**). Other restricted agents are noted in APeX.

An approving clinician's ID number is needed to order a restricted agent. To obtain approval for a restricted agent, call Pediatric ASP between 8am-5pm M-F. For off-hours approval (until 9pm) contact the Pediatric ID Consult Service. From 9pm-8am, use approval ID# 11111 for release of a single dose, then contact ASP for approval of subsequent doses.

Dosing recommendations are for usual doses to treat the most common conditions.

For additional indication-specific dosing, or agents not included below, refer to the

**Pediatric Empiric Antimicrobial Therapy Guidelines (EATG)** ([idmp.ucsf.edu](http://idmp.ucsf.edu)), or **Lexi-Comp**.

Consult pharmacist or [kdpnet.kdp.louisville.edu/drugbook/pediatric](http://kdpnet.kdp.louisville.edu/drugbook/pediatric) for renal dose adjustment.

IV-PO = High oral bioavailability alternative – Consider IV to PO Switch; LD = loading dose; MD = maintenance dose

Cost estimates based on Average Wholesale Price for 20kg child at usual dose (\$ ≤\$30/day; \$\$ \$30-100/day; \$\$\$ >\$100/day)

Drug	Usual Dose	Dose Adjustment	Maximum Dose
<b>Acyclovir IV</b> \$	<b>Mucocutaneous HSV Infection Immunocompetent Host ≥3 mo</b> 5mg/kg/dose q8h	Adjust for CrCl < 50 ml/min/1.73m <sup>2</sup>	None
	<b>CNS HSV Infection ≥3 mo-&lt;12 yo</b> 15mg/kg/dose q8h		
	<b>CNS HSV ≥12 yo, HSV in Immunocompromised Host, or VZV Infection</b> 10mg/kg/dose q8h		
	<b>HSV Infection &lt;3mo</b> 20mg/kg/dose q8h		
Acyclovir PO preferred for non-invasive infection in immunocompetent host >3 months old – refer to <b>Pediatric EATG</b> or <b>Lexi-Comp</b> for dose ( <a href="http://idmp.ucsf.edu">idmp.ucsf.edu</a> )			
<b>Amphotericin B Liposomal IV</b> <sup>ID-R</sup> (AmBisome®) \$\$\$	5mg/kg/dose q24h	No recommended dose adjustment for renal dysfunction, but drug should be used with caution due to nephrotoxicity risk	None
	**Lower dose may be appropriate for certain infections – consult ID pharmacist**		
<b>Ampicillin IV</b> <sup>IV-PO</sup> \$\$	50mg/kg/dose q6h <b>Endocarditis, Meningitis</b> 300mg/kg/day divided q4-6h	Adjust for CrCl < 50 ml/min/1.73m <sup>2</sup>	2g/dose
<b>Ampicillin-sulbactam IV</b> <sup>IV-PO</sup> (Unasyn®) \$\$	50mg ampicillin/kg/dose q6h	Adjust for CrCl < 50 ml/min/1.73m <sup>2</sup>	<b>Usual Max</b> 2g ampicillin q6h
<b>Amoxicillin PO</b> \$	25mg/kg/dose BID	Adjust for CrCl < 50 ml/min/1.73m <sup>2</sup>	<b>Usual Max</b> 1g BID
	<b>High Dose (Pneumococcal)</b> 45mg/kg/dose BID		<b>Absolute Max</b> 2g BID
Refer to <b>Pediatric EATG</b> ( <a href="http://idmp.ucsf.edu">idmp.ucsf.edu</a> ) for dosing specific to indication, guidance on formulations and maximum dosing by indication			
<b>Amoxicillin-clavulanate PO</b> (Augmentin®) \$-\$\$	<b>&lt;3 mo:</b> 15mg amox/kg/dose BID (Use 125mg/5ml suspension)	Adjust for CrCl < 50 ml/min/1.73m <sup>2</sup>	<b>Usual Max</b> Susp: 1000mg BID Tablet: 875mg BID
	<b>Standard Dose ≥3 mo</b> 22.5mg amox/kg/dose BID (Use 400mg/5ml suspension)		
	<b>High Dose (Pneumococcal)</b> 45mg amox/kg/dose BID (Use 600mg/5ml suspension <40kg, 400mg/5ml suspension ≥40kg)		
<b>Caspofungin IV</b> <sup>ID-R</sup> \$\$\$	<b>1-3 mo:</b> 25mg/m <sup>2</sup> /dose q24h <b>≥3 mo:</b> LD 70mg/m <sup>2</sup> /dose x1 then MD 50mg/m <sup>2</sup> /dose q24h	Adjust MD for severe hepatic dysfunction 70mg/m <sup>2</sup> x 1, then 35mg/m <sup>2</sup> q24h	LD: 70mg MD: 50mg q24h
<b>Cefazolin IV</b> \$	<b>Mild-Moderate Infection</b> 25mg/kg/dose q8h	Adjust for CrCl < 70 ml/min/1.73m <sup>2</sup>	<b>Mild-Moderate</b> 1g q8h
	<b>Severe Infection</b> 50mg/kg/dose q8h		<b>Severe</b> 2g q8h
<b>Cephalexin PO</b> \$	<b>Mild Infection (e.g. Cystitis)</b> 25mg/kg/dose BID	Adjust for CrCl < 50 ml/min/1.73m <sup>2</sup>	<b>Usual Max</b> 500mg/dose
	<b>Moderate Infection (e.g. Cellulitis)</b> 25mg/kg/dose TID		<b>Absolute Max (Severe Infection)</b> 1g/dose
	<b>Severe Infection (e.g. Bone/Joint)</b> 33mg/kg/dose TID		
Refer to <b>Pediatric EATG</b> ( <a href="http://idmp.ucsf.edu">idmp.ucsf.edu</a> ) for dosing specific to indication, and maximum dosing by indication			
<b>Cefepime IV</b> \$	50mg/kg/dose q12h <b>CF/Pseudomonas/ Febrile Neutropenia/Meningitis</b> 50mg/kg/dose q8h	Adjust for CrCl < 50 ml/min/1.73m <sup>2</sup>	2g q12h <b>High Dose</b> 2g q8h
<b>Ceftazidime IV</b> \$\$	50mg/kg/dose q8h	Adjust for CrCl < 50 ml/min/1.73m <sup>2</sup>	2g q8h

Drug	Usual Dose	Dose Adjustment	Maximum Dose
<b>Ceftriaxone IV</b> \$	50mg/kg/dose q24h  <b>Meningitis</b> 50mg/kg/dose q12h	No adjustment	1g q24h  <b>Meningitis</b> 2g q12h
<b>Ciprofloxacin<sup>IV-PO*</sup></b> *IV:PO Ratio 1:1 until adult doses, then 4:5 \$	10-15mg/kg/dose q12h  <b>Cystic Fibrosis</b> 20mg/kg/dose PO q12h 15mg/kg/dose IV q12h	Adjust for CrCl < 50 ml/min/1.73m <sup>2</sup>	750mg PO q12h 400mg IV q8h  <b>Cystic Fibrosis</b> 1000mg PO q12h 600mg IV q8h
	<b>**For Pseudomonas Infection, go up to maximum dose**</b>		
<b>Clindamycin<sup>IV-PO*</sup></b> \$	10mg/kg/dose q8h  <b>Bone/Joint Infection</b> 13 mg/kg/dose q8h	No adjustment	<b>PO:</b> 600mg q8h <b>IV:</b> 900mg q8h
<b>Fluconazole<sup>IV-PO</sup></b> \$	<b>Invasive Candidiasis</b> 12mg/kg/dose q24h	Adjust for CrCl < 50 ml/min/1.73m <sup>2</sup>	800mg q24h <i>Varies by site and severity</i>
<b>Gentamicin IV</b> \$	<b>Gram Negative Infection</b> 2.5mg/kg/dose q8h	Adjust for CrCl < 50 ml/min/1.73m <sup>2</sup>	None
	<b>**Consult pharmacist for dose adjustment/level assessment**</b>		
<b>Levofloxacin<sup>IV-PO</sup></b> \$	<b>6 mo-&lt;5 yo:</b> 10mg/kg/dose q12h <b>≥5 yo:</b> 10mg/kg/dose q24h	Adjust for CrCl < 50 ml/min/1.73m <sup>2</sup>	750mg q24h
<b>Meropenem IV</b> \$\$	20mg/kg/dose q8h  <b>Cystic Fibrosis/Meningitis</b> 40mg/kg/dose q8h 10mg/kg/dose q8h	Adjust for CrCl < 50 ml/min/1.73m <sup>2</sup>	1g q8h <b>CF/Meningitis</b> 2g q8h
<b>Metronidazole<sup>IV-PO</sup></b> \$	<b>Appendicitis/Intra-Abdom. Infection</b> 30mg/kg/dose q24h	Adjust for CrCl < 50 ml/min/1.73m <sup>2</sup>	1500mg/day
<b>Nafcillin IV</b> \$\$	50mg/kg/dose q6h	Adjust for concurrent hepatic and renal dysfunction	<b>Individual Dose</b> 2g/dose <b>Daily Dose</b> 12g/DAY
<b>Piperacillin/Tazobactam IV</b> (Zosyn®) \$\$	80mg piperacillin/kg/dose q6h  <b>CF/Pseudomonas/Serious Infection</b> 100mg piperacillin/kg/dose q6h	Adjust for CrCl < 50 ml/min/1.73m <sup>2</sup>	4g piperacillin q6h
<b>Tobramycin IV</b> \$	2.5mg/kg/dose q8h  <b>Cystic Fibrosis</b> 10mg/kg/dose q24h	Adjust for CrCl < 50 ml/min/1.73m <sup>2</sup>	None
	<b>**Consult pharmacist for dose adjustment/level assessment**</b>		
<b>TMP/SMX<sup>IV-PO</sup></b> (Bactrim®, Septra®) \$	<b>Mild to Moderate Infection</b> 5mg/kg/dose TMP BID  <b>CF/Serious Infection/PCP</b> 5mg/kg/dose TMP q6-8h	Adjust for CrCl < 30 ml/min/1.73m <sup>2</sup>	<b>Mild-Moderate</b> 160mg TMP/dose  (no max for severe)
<b>Vancomycin IV</b> \$	<b>3mo-&lt;12yo:</b> 17.5mg/kg/dose Q6H* <b>≥12yo:</b> 15mg/kg/dose Q6H*  *Consult pharmacy for pt-specific dosing	Consider q8-12h interval for <b>Cardiac Dysfunction/CICU</b>  Consult pharmacy for dose adjustment and level assessment	<b>Initial Max</b> 4g/day
<b>Voriconazole IV<sup>D-R</sup></b> \$\$\$	<b>2-&lt;12 yo OR 12-14 yo and &lt; 50kg:</b> LD: 9mg/kg/dose q12h x 2, then MD: 8mg/kg/dose q12h  <b>&gt;14 yo OR 12-14 yo and ≥ 50kg:</b> LD: 6mg/kg/dose q12h x 2, then MD: 4mg/kg/dose q12h	No adjustment for renal dysfunction but avoid IV formulation if CrCl < 50 ml/min/1.73m <sup>2</sup>	<b>IV:</b> No max  <b>PO Initial Max Maintenance Dose</b> <b>2-&lt;12 yo OR 12-14 yo and &lt; 50kg:</b> 350mg/dose
<b>Voriconazole PO<sup>D-R</sup></b> \$\$	<b>2-&lt;12 yo OR 12-14 yo and &lt; 50kg:</b> 9mg/kg/dose BID  <b>&gt;14 yo OR 12-14 yo and ≥ 50kg:</b> LD: 400mg/dose BID x 2, then 200mg/dose BID  <b>**For IV and PO, therapeutic drug monitoring recommended with first trough level after 5 days on stable dose – consult ID/ASP pharmacist for guidance**</b>	Avoid if severe hepatic dysfunction, decrease MD by 50% for mild-moderate hepatic dysfunction	<b>PO Initial Max Maintenance Dose</b> <b>&gt;14 yo OR 12-14 yo and ≤ 50kg:</b> 200mg/dose

### Antibiotic Spectrum Guide

This is a simplified table that does not apply to all scenarios. See idmp.ucsf.edu for hospital-specific susceptibilities.

	Vancomycin	Ampicillin, Amoxicillin	Nafcillin	Unasyn, Augmentin	Cefazolin, Cephalexin	Ceftriaxone	Ceftazidime	Cefepime	Piperacillin/tazobactam	Ertapenem	Meropenem	Azithromycin (respiratory)	Ciprofloxacin	Levofloxacin	TMP/SMX (non-sepsis)	Clindamycin	Doxycycline	Metronidazole
<i>Enterococcus</i>																		
MRSA																		
MSSA																		
<i>Streptococcus pneumoniae</i>																		
β-hemolytic strep (e.g. GAS, GBS)																		
Gram negatives: community																		
Gram negatives: hospital																		
<i>Enterobacter</i> , other AmpC-producers																		
<i>Pseudomonas</i>																		
ESBL-producers																		
Mouth anaerobes																		
Gut anaerobes																		
Atypicals																		

Shading Key:  good to excellent activity  some activity  little to no activity